Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα.
about
Cyclin-dependent kinase inhibitor therapy for hematologic malignanciesDinaciclib (SCH727965) inhibits the unfolded protein response through a CDK1- and 5-dependent mechanismC/EBPα and MYB regulate FLT3 expression in AMLTargeting cell cycle regulators in hematologic malignancies.A Cell-Based High-Throughput Screening for Inducers of Myeloid Differentiation.CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.Acetylation of C/EBPα inhibits its granulopoietic function.CDK1 interacts with RARγ and plays an important role in treatment response of acute myeloid leukemiaFetal and neonatal hematopoietic progenitors are functionally and transcriptionally resistant to Flt3-ITD mutations.FLT3 inhibitors: clinical potential in acute myeloid leukemia.T-LAK cell-originated protein kinase presents a novel therapeutic target in FLT3-ITD mutated acute myeloid leukemia.Therapeutic targeting the cell division cycle 25 (CDC25) phosphatases in human acute myeloid leukemia--the possibility to target several kinases through inhibition of the various CDC25 isoforms.Astrocytes require insulin-like growth factor I to protect neurons against oxidative injury.C/EBPα in normal and malignant myelopoiesis.Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia.Emerging cell cycle inhibitors for acute myeloid leukemia.5-Aminoimidazole-4-carboxamide ribonucleoside induces differentiation of acute myeloid leukemia cells.Antileukemic effects of midostaurin in acute myeloid leukemia - the possible importance of multikinase inhibition in leukemic as well as nonleukemic stromal cells.Identification of novel kinase inhibitors by targeting a kinase-related apoptotic protein-protein interaction network in HeLa cells.C/EBPα deregulation as a paradigm for leukemogenesis.Targeting self-renewal pathways in myeloid malignancies.The Impact of FLT3 Mutations on the Development of Acute Myeloid Leukemias.HOXA9 is critical in the proliferation, differentiation, and malignancy of leukaemia cells both in vitro and in vivo.
P2860
Q24561485-8A76BD7B-0F18-47DF-990C-077460F619B9Q34393767-C2D4CD76-1127-464B-B897-CE101EED2BC2Q34425939-FCE118EF-8E65-48AD-9C1C-2024D16ABF61Q35334436-E8925A54-D2DE-4335-A181-F960F23DE304Q36075321-F0C72E3E-B3EF-4569-8400-F24326EF3481Q36545966-7B81DE12-2D50-403A-90CE-8FF9204A24DDQ36747244-D48F496E-7FDE-4792-94E3-A29B1A19A23DQ36906246-3C1B7B70-3A69-41D8-A5A7-01B6A933C2AEQ37496355-FBBE1674-4DB9-4CAF-A290-9A071CB17CDEQ37638749-BD2C4163-88CD-4B87-9668-C2AB655899AAQ38261327-46B4D345-9AB3-4A4F-8C46-1247E62B25ABQ38268221-3A1D17D9-8D6B-4885-9188-72D18613C85CQ38273037-D8FA9318-AFF3-478E-B4EC-24FB3C4C7CC5Q38370875-A65EB44D-3FAB-4E8F-8091-07C8CBC95D09Q38701483-5716A7DE-32C9-4223-B801-63D72B8E2BA1Q38785380-047EB70E-278E-4C8F-B1F2-AC6384CDDE3DQ39041458-E748A008-DA94-404B-8D80-4157DC768CD1Q39045977-064EE139-5EDC-4CD2-A53C-5A56EA6E089FQ39227830-DEAB7E75-9824-45FC-A19B-486B90317029Q39442731-B7D3C28B-2E82-4EF9-8275-6FEE6F25480AQ41104001-84A437E9-C98E-4AF5-885D-2EA9202F0B34Q43070849-D3367993-F81E-4B18-AEF9-BCF96A427879Q45872606-8DECD3D6-8DCB-4729-A7E3-1C879C59179D
P2860
Targeting CDK1 promotes FLT3-activated acute myeloid leukemia differentiation through C/EBPα.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Targeting CDK1 promotes FLT3-a ...... ifferentiation through C/EBPα.
@ast
Targeting CDK1 promotes FLT3-a ...... ifferentiation through C/EBPα.
@en
type
label
Targeting CDK1 promotes FLT3-a ...... ifferentiation through C/EBPα.
@ast
Targeting CDK1 promotes FLT3-a ...... ifferentiation through C/EBPα.
@en
prefLabel
Targeting CDK1 promotes FLT3-a ...... ifferentiation through C/EBPα.
@ast
Targeting CDK1 promotes FLT3-a ...... ifferentiation through C/EBPα.
@en
P2093
P2860
P356
P1476
Targeting CDK1 promotes FLT3-a ...... differentiation through C/EBPα
@en
P2093
Britta Will
David Gonzalez
Hanna S Radomska
Meritxell Alberich-Jordà
Ruud Delwel
P2860
P304
P356
10.1172/JCI43354
P407
P577
2012-07-17T00:00:00Z